Life Sciences Bit: Amendment of the Code of Conduct for Pharmaceutical Advertising
The Code of Conduct for Pharmaceutical Advertising (Code of Conduct) (In Dutch: Gedragscode Geneesmiddelenreclame) has been amended as of 1 July, 2018. The changes come as a response to the amendments to the policy rules providing guidance on the ban of inducements regarding medicinal products, which entered into force 1 April, 2018 (Policy Rules) (In Dutch: Beleidsregels gunstbetoon Geneesmiddelenwet 2018).
The most notable changes of the Policy Rules, and as a result of the Code of Conduct, concern the introduction of a regulatory framework for financial relationships that do not fall under the definition of inducement. Those relationships relate to non-professionals, sponsorship of projects and academic awards.
Furthermore, the scope of exemptions regarding inducements for professionals and regarding hospitality at (scientific) meetings and other events has been slightly altered.
Our Life Sciences team advises about the Code of Conduct and in a regular manner represents companies in proceedings with the Code commission for Pharmaceutical Advertising (In Dutch: Codecommissie van de Stichting Code Geneesmiddelenreclame) with respect to alleged infringements on the Code for Pharmaceutical Advertising.
Should you have queries, please contact Jacobine van Beijeren or your trusted Loyens & Loeff adviser.
Jacobine.van.Beijeren@loyensloeff.com / +31 10 224 61 93
Follow our Showcase Page on LinkedIn for updates and more Life Sciences Bits.